An Increase in C-Reactive Protein Levels during Antidepressant Treatment as a Candidate Marker for Treatment Nonresponse in Major Depressive Disorder
Neuropsychobiology · 30.03.2026 · 1-12
DOI: 10.1159/000551623 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychobiology, online erschienen am 30.03.2026. Verfasst von Marius Solon Etzel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Max Planck Institute of Psychiatry, Munich, Germany. Hauptthemen laut MEDLINE: C-Reactive Protein, Major Depressive Disorder, Antidepressive Agents. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Introduction
One-third of patients with major depressive disorder (MDD) exhibit low-grade inflammation as reflected by C-reactive protein (CRP) concentrations >3 mg/L. We explored whether CRP changes from baseline to week one of antidepressant treatment (ΔCRP) can serve as a marker of treatment response.
Methods
CRP serum levels were measured at baseline and after the first week of treatment in 33 MDD patients and correlated with patients’ Hamilton Depression Rating Scale (HAM-D), while adjusting for age, gender, and body mass index. We assessed antidepressant responses at weeks one and four of treatment as a >25% and >50% HAM-D score reduction (ΔHAM-D) compared to baseline, respectively. We compared baseline and week-one CRP levels with the paired t test within responders and nonresponders separately and ΔCRP between the groups with the ANCOVA.
Results
Higher ΔCRP correlated with lower week-four ΔHAM-D scores (r = −0.5, p = 0.006). Nonresponders showed higher ΔCRP – but not baseline and week-one CRP – than responders (p = 0.018, Cohen’s d = 1.1). A ΔCRP increase was observed in 13/16 (81%) nonresponders and 7/17 (41%) responders (Fisher’s exact test’s p = 0.03). A ΔCRP increase combined with a week-one nonresponse was observed in 13/16 (81%) nonresponders and 1/17 (6%) responders (p < 0.0001).
Conclusions
Rather ΔCRP at week one than baseline CRP might be indicative of treatment response at week four, especially if combined with week-one ΔHAM-D. In the future, ΔCRP could be introduced into psychiatric practice to guide treatment plans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Max Planck Institute of Psychiatry, Munich, Germany.
- Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands, yevgenia.rozenblum@donders.ru.nl.
- Radboud University Medical Center, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands.
- Psychiatric Services Solothurn and Faculty of Medicine of University of Basel, Solothurn, Switzerland.
- Max Planck Institute of Psychiatry, Munich, Germany, p@wlowski.de.
Zitieren
APA
Etzel, M. S., Rosenblum, Y., Dresler, M., Steiger, A., Mikoteit, T., & Zeising, M. (2026). An Increase in C-Reactive Protein Levels during Antidepressant Treatment as a Candidate Marker for Treatment Nonresponse in Major Depressive Disorder. Neuropsychobiology, 1-12. https://doi.org/10.1159/000551623
Vancouver
Etzel MS, Rosenblum Y, Dresler M, Steiger A, Mikoteit T, Zeising M. An Increase in C-Reactive Protein Levels during Antidepressant Treatment as a Candidate Marker for Treatment Nonresponse in Major Depressive Disorder. Neuropsychobiology. 2026:1-12. doi:10.1159/000551623
BibTeX
@article{Etzel2026,
author = {Etzel, Marius Solon and Rosenblum, Yevgenia and Dresler, Martin and Steiger, Axel and Mikoteit, Thorsten and Zeising, Marcel},
title = {An Increase in C-Reactive Protein Levels during Antidepressant Treatment as a Candidate Marker for Treatment Nonresponse in Major Depressive Disorder},
journal = {Neuropsychobiology},
year = {2026},
pages = {1--12},
doi = {10.1159/000551623}
}
EUVIMED